{"success":true,"data":{"pressRelease":{"id":"108527","rtpr_id":"nBw1rNSB8a","ticker":"ACAD","exchange":"NASDAQ","all_tickers":["ACAD"],"title":"Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results","author":"Business Wire","published_at":"2026-08-04T20:05:00.467Z","article_body":"Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results\n\n- Second quarter DAYBUE(®) GAAP net sales of $125 million, up 30%\nyear-over-year driven by strong uptake of DAYBUE STIX\n\n- Second quarter NUPLAZID(®) GAAP net sales of $183 million, up 10%\nyear-over-year on a non-GAAP adjusted basis\n\n- Increased full year 2026 total revenue guidance to $1.24 to $1.30 billion,\nreflecting higher DAYBUE guidance of $480 to $510 million and reaffirmed\nNUPLAZID guidance of $760 to $790 million\n\n- Topline results from the Phase 2 remlifanserin study in Alzheimer’s\ndisease psychosis anticipated September to October 2026\n\nAcadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial\nresults for the second quarter ended June 30, 2026.\n\n“Acadia delivered an outstanding second quarter, highlighted by strong\ncommercial execution across both DAYBUE and NUPLAZID, resulting in total\nrevenue growth of 17% year-over-year on an adjusted basis,” said Catherine\nOwen Adams, Chief Executive Officer of Acadia. “For DAYBUE, continued\npatient demand and robust uptake of STIX drove another quarter of strong\nperformance. For NUPLAZID, we continued to see strong momentum, especially in\nnew-to-brand prescriptions as our recently expanded sales force gained\ntraction in the field. We remain confident that both franchises are on track\nto achieve our long-term ambition of approximately $1.7 billion in annual net\nsales in 2028. Looking ahead, we are excited about the anticipated topline\nresults from our Phase 2 program evaluating remlifanserin in Alzheimer's\ndisease psychosis in the September to October timeframe, which we believe\nrepresents a potentially transformational opportunity for Acadia.”\n\nCompany Updates\n\n\n * Completed enrollment in the Phase 2 portion of the RADIANT program evaluating\nremlifanserin in Alzheimer's disease psychosis and initiated Phase 3 screening\nand enrollment; topline Phase 2 results are expected in September to October\n2026.\n\n * Received FDA Fast Track designation for remlifanserin for the treatment of\nhallucinations and delusions associated with Alzheimer's disease psychosis,\nrecognizing its potential to address a significant unmet medical need.\n\n * The Committee for Medicinal Products for Human Use (CHMP) of the European\nMedicines Agency (EMA) adopted a positive opinion recommending marketing\nauthorization for DAYBU(®) (trofinetide) for the treatment of neurobehavioral\nsymptoms of Rett syndrome in adults and pediatric patients aged five years and\nolder. If approved by the European Commission, DAYBU would become the first\nauthorized treatment for Rett syndrome in the European Union.\n\nFinancial Results\n\nRevenues\n\nGAAP total revenues, comprised of net product sales from NUPLAZID and DAYBUE,\nwere $308 million for the second quarter of 2026, up 16% as compared to GAAP\ntotal revenues of $265 million in the second quarter of 2025, and up 17% as\ncompared to non-GAAP adjusted total revenues of $262 million in the second\nquarter of 2025.\n\nGAAP net product sales of NUPLAZID were $183 million for the second quarter of\n2026, up 9% compared to GAAP net product sales of $168 million for the second\nquarter of 2025, and up 10% as compared to non-GAAP adjusted net product sales\nof $166 million for the second quarter of 2025.\n\nNet product sales of DAYBUE were $125 million for the second quarter of 2026,\nan increase of 30% as compared to $96 million for the second quarter of 2025.\n\nA reconciliation of NUPLAZID non-GAAP adjusted net product sales and non-GAAP\nadjusted total revenues is provided in Table 1. A description of these\nadjustments is included under ‘Non-GAAP Financial Measures.’\n\nResearch and Development\n\nResearch and development expenses for the second quarter of 2026 were $82\nmillion, compared to $78 million for the same period of 2025.\n\nSelling, General and Administrative\n\nSelling, general and administrative expenses for the second quarter of 2026\nwere $160 million, compared to $134 million for the same period of 2025.\n\nNet Income\n\nFor the second quarter of 2026, Acadia reported net income of $32 million, or\n$0.18 per diluted share, compared to a net income of $27 million, or $0.16 per\ndiluted share, for the same period in 2025.\n\nCash and Investments\n\nAt June 30, 2026, Acadia’s cash, cash equivalents, and investment securities\ntotaled $956 million, compared to $820 million at December 31, 2025.\n\nFull Year 2026 Financial Guidance (GAAP):\n\nAcadia is updating its 2026 guidance:\n\n\n * Total revenues revised to a range of $1.24 to $1.30 billion, up from the\nprevious range of $1.22 to $1.28 billion.\n\n * NUPLAZID net product sales in the range of $760 to $790 million.\n\n * DAYBUE (including all forms of trofinetide) global net product sales in the\nrange of $480 to $510 million, up from the previous range of $460 to $490\nmillion.\n\n * R&D expense in the range of $355 to $380 million, down from the previous\nrange of $385 to $410 million.\n\n * SG&A expense in the range of $660 to $700 million.\n\nConference Call and Webcast Information\n\nAcadia will host a conference call to discuss the second quarter 2026 results\ntoday, Tuesday, August 4, 2026 at 1:30 p.m. PT/4:30 p.m. ET. The conference\ncall may be accessed by registering for the call here\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F517709979&esheet=54583306&newsitemid=20260804047448&lan=en-US&anchor=here&index=1&md5=170f49a03048b033f2fa74de26470fd9)\n. Once registered, participants will receive an email with the dial-in number\nand unique PIN number to use for accessing the call.\n\nAbout NUPLAZID(®) (pimavanserin)\n\nPimavanserin is a selective serotonin inverse agonist and antagonist\npreferentially targeting 5-HT2A receptors. These receptors are thought to play\nan important role in neuropsychiatric disorders. In vitro, pimavanserin\ndemonstrated no appreciable binding affinity for dopamine (including D2),\nhistamine, muscarinic, or adrenergic receptors. Pimavanserin was approved for\nthe treatment of hallucinations and delusions associated with Parkinson’s\ndisease psychosis by the U.S. Food and Drug Administration in April 2016 under\nthe trade name NUPLAZID.\n\nAbout DAYBUE(®) (trofinetide)\n\nTrofinetide is a synthetic version of a naturally occurring molecule known as\nthe tripeptide glycine-proline-glutamate (GPE). The mechanism by which\ntrofinetide exerts therapeutic effects in patients with Rett syndrome is\nunknown. Trofinetide was approved for the treatment of Rett syndrome in adults\nand pediatric patients 2 years of age and older by the U.S. Food and Drug\nAdministration in March 2023 under the trade name DAYBUE or DAYBUE STIX.\n\nAbout Acadia Pharmaceuticals\n\nAcadia is committed to turning scientific promise into meaningful innovation\nthat makes the difference for underserved neurological and rare disease\ncommunities around the world. Our commercial portfolio includes the first and\nonly FDA-approved treatments for Parkinson’s disease psychosis and Rett\nsyndrome. We are developing the next wave of therapeutic advancements with a\nrobust and diverse pipeline that includes mid- to late-stage programs in\nAlzheimer’s disease psychosis and Lewy body dementia psychosis, along with\nearlier-stage programs that address other underserved patient needs. At\nAcadia, we’re here to be their difference. For more information, visit us at\nacadia.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Facadia.com%2Fen-us&esheet=54583306&newsitemid=20260804047448&lan=en-US&anchor=acadia.com&index=2&md5=4a4dbb4742aedbe7d7bad615239cfb11)\nand follow us on LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Facadia-pharmaceuticals%2F&esheet=54583306&newsitemid=20260804047448&lan=en-US&anchor=LinkedIn&index=3&md5=d76c8820ebbfd263779a4d92e6e39f04)\nand X\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fx.com%2Facadiapharma&esheet=54583306&newsitemid=20260804047448&lan=en-US&anchor=X&index=4&md5=29e4d1116ca0e6094c888510ca369e89)\n.\n\nNon-GAAP Financial Measures\n\nThis press release contains the following financial measures that do not\ncomply with U.S. generally accepted accounting principles (GAAP): non-GAAP\nadjusted net product sales for NUPLAZID for the second quarter of 2025 and\nnon-GAAP adjusted total revenues for the second quarter of 2025. In preparing\nthese non-GAAP financial results, the Company includes adjustments made to\nreflect the impact of a change in estimate related to NUPLAZID IRA rebate\naccruals. Please refer to our press release dated February 25, 2026, for\nadditional details. These non-GAAP financial measures complement GAAP results\nand are used by management to analyze financial performance and evaluate\nperiod-to-period changes. Management believes these non-GAAP financial\nmeasures are useful to investors and other users of the Company’s financial\nstatements to facilitate period-to-period comparability. These non-GAAP\nfinancial measures are not meant to be considered as a substitute for\ncomparable GAAP measures; should be read in conjunction with the Company’s\nconsolidated financial statements prepared in accordance with GAAP; have no\nstandardized meaning prescribed by GAAP; and are unlikely to be comparable\nwith non-GAAP disclosures released by other companies.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Forward-looking\nstatements include all statements other than statements of historical fact and\ncan be identified by terms such as “may,” “will,” “should,”\n“could,” “would,” “expects,” “plans,” “anticipates,”\n“believes,” “estimates,” “projects,” “predicts,”\n“potential,” “guidance,” “continue” and similar expressions\n(including the negative thereof) intended to identify forward-looking\nstatements. Forward-looking statements contained in this press release,\ninclude, but are not limited to, statements about: (i) our business strategy,\nobjectives and opportunities, including support for and innovations in our\npipeline assets and business development opportunities, sales growth for\nDAYBUE and uptake in DAYBUE STIX, and potential for enhanced shareholder\nvalue; (ii) the momentum and expectations for NUPLAZID with the expanded sales\nforce, (iii) the FDA’s potential review of a new drug application for\nremlifanserin as a treatment for Alzheimer’s disease psychosis, (iv) the\nreceipt and timing of the topline results of the RADIANT Phase 2 study, the\ntransformational opportunity of those results, and the enrollment of the Phase\n3 portion of the RADIANT development program, (v) potential approval of DAYBU\n(trofinetide) in the European Union, (vi) plans for, including timing,\ndevelopment and progress of commercialization or regulatory timelines for our\nproducts and our product candidates; (vii) benefits to be derived from and\nefficacy of our products, including the potential advantages of our products;\nand (viii) our estimates regarding our future financial performance,\nprofitability, capital requirements or expenses, including our full year 2026\nfinancial guidance and anticipated net product sales by the end of 2028.\nForward-looking statements are subject to known and unknown risks,\nuncertainties, assumptions and other factors that may cause our actual\nresults, performance or achievements to differ materially and adversely from\nthose anticipated or implied by our forward-looking statements. Such risks,\nuncertainties and other factors include, but are not limited to: our\ndependency on the continued successful commercialization of our products and\nour ability to maintain or increase sales of our products; the success of our\nplans to continue commercial growth; the costs of our commercialization plans\nand development programs, and the financial impact or revenues from any\ncommercialization we undertake; our ability to obtain necessary regulatory\napprovals for our product candidates and, if and when approved, market\nacceptance of our products; the risks associated with clinical trials and\ntheir outcomes, including risks of unsuccessful enrollment and negative or\ninconsistent results; our dependence on third-party collaborators, clinical\nresearch organizations, manufacturers, suppliers and distributors; the impact\nof competitive products and therapies; our ability to generate or obtain the\nnecessary capital to fund our operations; our ability to grow, equip and train\nour specialized sales forces; our ability to manage the growth and complexity\nof our organization; our ability to maintain, protect and enhance our\nintellectual property; and our ability to continue to stay in compliance with\napplicable laws and regulations. Given the risks and uncertainties, you should\nnot place undue reliance on these forward-looking statements. For a discussion\nof these and other risks, uncertainties and other factors that may cause our\nactual results, performance or achievements to differ, please refer to our\nannual report on Form 10-K for the year ended December 31, 2025 as well as our\nsubsequent filings with the Securities and Exchange Commission from time to\ntime. The forward-looking statements contained herein are made as of the date\nhereof, and we undertake no obligation to update them after this date, except\nas required by law.\n ACADIA PHARMACEUTICALS INC.                                                                                                              \n \n                                                                                                                                        \n \nCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS                                                                                         \n \n                                                                                                                                        \n \n(in thousands, except per share amounts)                                                                                                \n \n                                                                                                                                        \n \n(Unaudited)                                                                                                                             \n                                                                                                                                          \n                                                  Three Months Ended June 30,                   Six Months Ended June 30,                 \n                                                  2026                     2025                 2026                     2025             \n Revenues                                                                                                                                 \n Product sales, net                               $       307,959          $       264,566      $       576,021          $       508,882  \n Total revenues                                           307,959                  264,566              576,021                  508,882  \n Operating expenses                                                                                                                       \n Cost of product sales ((1)(2))                           28,316                   20,734               53,107                   41,126   \n Research and development ((2))                           81,555                   77,951               158,423                  156,216  \n Selling, general and administrative ((2))                160,252                  133,507              331,271                  259,877  \n Total operating expenses                                 270,123                  232,192              542,801                  457,219  \n (Loss) income from operations                            37,836                   32,374               33,220                   51,663   \n Interest income, net                                     7,990                    7,243                16,045                   15,144   \n Other income                                             647                      594                  1,189                    1,183    \n Income before income taxes                               46,473                   40,211               50,454                   67,990   \n Income tax expense                                       14,973                   13,545               15,317                   22,337   \n Net income                                       $       31,500           $       26,666       $       35,137           $       45,653   \n Earnings per share:                                                                                                                      \n Basic                                            $       0.18             $       0.16         $       0.21             $       0.27     \n Diluted                                          $       0.18             $       0.16         $       0.20             $       0.27     \n Weighted average common shares outstanding:                                                                                              \n Basic                                                    171,603                  167,827              171,063                  167,321  \n Diluted                                                  172,851                  168,681              172,890                  168,219  \n                                                                                                                                          \n ((1)) Includes license fees and royalties                                                                                                \n                                                                                                                                          \n ((2)) Includes the following stock-based compensation expense                                                                            \n                                                                                                                                          \n Cost of product sales                            $       510              $       18           $       838              $       352      \n Research and development                         $       4,746            $       4,477        $       8,888            $       7,910    \n Selling, general and administrative              $       11,684           $       9,845        $       21,912           $       17,458   \n\n ACADIA PHARMACEUTICALS INC.                                                                      \n \n                                                                                                \n \nCONDENSED CONSOLIDATED BALANCE SHEETS                                                           \n \n                                                                                                \n \n(in thousands)                                                                                  \n \n                                                                                                \n \n(Unaudited)                                                                                     \n                                                                                                  \n                                                       June 30,               December 31,        \n                                                       \n2026                  \n2025               \n                                                       (unaudited)                                \n Assets                                                                                           \n Cash, cash equivalents and investment securities      $       956,474        $        819,686    \n Accounts receivable, net                                      150,642                 121,457    \n Interest and other receivables                                15,688                  26,774     \n Inventory                                                     32,372                  34,670     \n Prepaid expenses and other current assets                     69,369                  59,526     \n Total current assets                                          1,224,545               1,062,113  \n Property and equipment, net                                   17,107                  7,511      \n Operating lease right-of-use assets                           69,424                  47,354     \n Intangible assets, net                                        103,448                 108,893    \n Restricted cash                                               7,846                   7,845      \n Long-term inventory                                           76,301                  76,704     \n Deferred tax assets                                           240,679                 249,879    \n Other assets                                                  3,550                   3,896      \n Total assets                                          $       1,742,900      $        1,564,195  \n Liabilities and stockholders’ equity                                                             \n Accounts payable                                      $       44,566         $        10,903     \n Accrued liabilities                                           316,870                 266,211    \n Total current liabilities                                     361,436                 277,114    \n Operating lease liabilities                                   59,547                  40,554     \n Other long-term liabilities                                   15,308                  19,137     \n Total liabilities                                             436,291                 336,805    \n Total stockholders’ equity                                    1,306,609               1,227,390  \n Total liabilities and stockholders’ equity            $       1,742,900      $        1,564,195  \n\n Table 1. ACADIA PHARMACEUTICALS INC.                                     \n \n                                                                        \n \nNON-GAAP RECONCILIATION                                                 \n \n                                                                        \n \n(in millions)                                                           \n \n                                                                        \n \n(Unaudited)                                                             \n                                                                          \n                                           2Q25               2Q26        \n GAAP NUPLAZID Net Sales                   $   168.5          $    183.2  \n Allocation of 2025 Amount                 $   (2.4   )       $    —      \n Non-GAAP Adjusted NUPLAZID Net Sales      $   166.1          $    183.2  \n DAYBUE products Net Sales                 $   96.1           $    124.8  \n Non-GAAP Adjusted Total Revenues          $   262.2          $    308.0  \n\n\n \n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260804047448/en/\n(https://www.businesswire.com/news/home/20260804047448/en/)\n\nInvestor Contact: \n\nAcadia Pharmaceuticals Inc.\n\nAl Kildani\n\n(858) 261-2872\n\nir@acadia-pharm.com (mailto:ir@acadia-pharm.com)\n\nAcadia Pharmaceuticals Inc.\n\nJessica Tieszen\n\n(858) 261-2950\n\nir@acadia-pharm.com (mailto:ir@acadia-pharm.com)\n\nMedia Contact: \n\nAcadia Pharmaceuticals Inc.\n\nDeb Kazenelson\n\n(818) 395-3043\n\nmedia@acadia-pharm.com (mailto:media@acadia-pharm.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw1rNSB8a","title":"Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results","author":"Business Wire","ticker":"ACAD","created":"2026-08-04T20:05:00.467Z","tickers":["ACAD"],"exchange":"NASDAQ","article_body":"Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results\n\n- Second quarter DAYBUE(®) GAAP net sales of $125 million, up 30%\nyear-over-year driven by strong uptake of DAYBUE STIX\n\n- Second quarter NUPLAZID(®) GAAP net sales of $183 million, up 10%\nyear-over-year on a non-GAAP adjusted basis\n\n- Increased full year 2026 total revenue guidance to $1.24 to $1.30 billion,\nreflecting higher DAYBUE guidance of $480 to $510 million and reaffirmed\nNUPLAZID guidance of $760 to $790 million\n\n- Topline results from the Phase 2 remlifanserin study in Alzheimer’s\ndisease psychosis anticipated September to October 2026\n\nAcadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial\nresults for the second quarter ended June 30, 2026.\n\n“Acadia delivered an outstanding second quarter, highlighted by strong\ncommercial execution across both DAYBUE and NUPLAZID, resulting in total\nrevenue growth of 17% year-over-year on an adjusted basis,” said Catherine\nOwen Adams, Chief Executive Officer of Acadia. “For DAYBUE, continued\npatient demand and robust uptake of STIX drove another quarter of strong\nperformance. For NUPLAZID, we continued to see strong momentum, especially in\nnew-to-brand prescriptions as our recently expanded sales force gained\ntraction in the field. We remain confident that both franchises are on track\nto achieve our long-term ambition of approximately $1.7 billion in annual net\nsales in 2028. Looking ahead, we are excited about the anticipated topline\nresults from our Phase 2 program evaluating remlifanserin in Alzheimer's\ndisease psychosis in the September to October timeframe, which we believe\nrepresents a potentially transformational opportunity for Acadia.”\n\nCompany Updates\n\n\n * Completed enrollment in the Phase 2 portion of the RADIANT program evaluating\nremlifanserin in Alzheimer's disease psychosis and initiated Phase 3 screening\nand enrollment; topline Phase 2 results are expected in September to October\n2026.\n\n * Received FDA Fast Track designation for remlifanserin for the treatment of\nhallucinations and delusions associated with Alzheimer's disease psychosis,\nrecognizing its potential to address a significant unmet medical need.\n\n * The Committee for Medicinal Products for Human Use (CHMP) of the European\nMedicines Agency (EMA) adopted a positive opinion recommending marketing\nauthorization for DAYBU(®) (trofinetide) for the treatment of neurobehavioral\nsymptoms of Rett syndrome in adults and pediatric patients aged five years and\nolder. If approved by the European Commission, DAYBU would become the first\nauthorized treatment for Rett syndrome in the European Union.\n\nFinancial Results\n\nRevenues\n\nGAAP total revenues, comprised of net product sales from NUPLAZID and DAYBUE,\nwere $308 million for the second quarter of 2026, up 16% as compared to GAAP\ntotal revenues of $265 million in the second quarter of 2025, and up 17% as\ncompared to non-GAAP adjusted total revenues of $262 million in the second\nquarter of 2025.\n\nGAAP net product sales of NUPLAZID were $183 million for the second quarter of\n2026, up 9% compared to GAAP net product sales of $168 million for the second\nquarter of 2025, and up 10% as compared to non-GAAP adjusted net product sales\nof $166 million for the second quarter of 2025.\n\nNet product sales of DAYBUE were $125 million for the second quarter of 2026,\nan increase of 30% as compared to $96 million for the second quarter of 2025.\n\nA reconciliation of NUPLAZID non-GAAP adjusted net product sales and non-GAAP\nadjusted total revenues is provided in Table 1. A description of these\nadjustments is included under ‘Non-GAAP Financial Measures.’\n\nResearch and Development\n\nResearch and development expenses for the second quarter of 2026 were $82\nmillion, compared to $78 million for the same period of 2025.\n\nSelling, General and Administrative\n\nSelling, general and administrative expenses for the second quarter of 2026\nwere $160 million, compared to $134 million for the same period of 2025.\n\nNet Income\n\nFor the second quarter of 2026, Acadia reported net income of $32 million, or\n$0.18 per diluted share, compared to a net income of $27 million, or $0.16 per\ndiluted share, for the same period in 2025.\n\nCash and Investments\n\nAt June 30, 2026, Acadia’s cash, cash equivalents, and investment securities\ntotaled $956 million, compared to $820 million at December 31, 2025.\n\nFull Year 2026 Financial Guidance (GAAP):\n\nAcadia is updating its 2026 guidance:\n\n\n * Total revenues revised to a range of $1.24 to $1.30 billion, up from the\nprevious range of $1.22 to $1.28 billion.\n\n * NUPLAZID net product sales in the range of $760 to $790 million.\n\n * DAYBUE (including all forms of trofinetide) global net product sales in the\nrange of $480 to $510 million, up from the previous range of $460 to $490\nmillion.\n\n * R&D expense in the range of $355 to $380 million, down from the previous\nrange of $385 to $410 million.\n\n * SG&A expense in the range of $660 to $700 million.\n\nConference Call and Webcast Information\n\nAcadia will host a conference call to discuss the second quarter 2026 results\ntoday, Tuesday, August 4, 2026 at 1:30 p.m. PT/4:30 p.m. ET. The conference\ncall may be accessed by registering for the call here\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F517709979&esheet=54583306&newsitemid=20260804047448&lan=en-US&anchor=here&index=1&md5=170f49a03048b033f2fa74de26470fd9)\n. Once registered, participants will receive an email with the dial-in number\nand unique PIN number to use for accessing the call.\n\nAbout NUPLAZID(®) (pimavanserin)\n\nPimavanserin is a selective serotonin inverse agonist and antagonist\npreferentially targeting 5-HT2A receptors. These receptors are thought to play\nan important role in neuropsychiatric disorders. In vitro, pimavanserin\ndemonstrated no appreciable binding affinity for dopamine (including D2),\nhistamine, muscarinic, or adrenergic receptors. Pimavanserin was approved for\nthe treatment of hallucinations and delusions associated with Parkinson’s\ndisease psychosis by the U.S. Food and Drug Administration in April 2016 under\nthe trade name NUPLAZID.\n\nAbout DAYBUE(®) (trofinetide)\n\nTrofinetide is a synthetic version of a naturally occurring molecule known as\nthe tripeptide glycine-proline-glutamate (GPE). The mechanism by which\ntrofinetide exerts therapeutic effects in patients with Rett syndrome is\nunknown. Trofinetide was approved for the treatment of Rett syndrome in adults\nand pediatric patients 2 years of age and older by the U.S. Food and Drug\nAdministration in March 2023 under the trade name DAYBUE or DAYBUE STIX.\n\nAbout Acadia Pharmaceuticals\n\nAcadia is committed to turning scientific promise into meaningful innovation\nthat makes the difference for underserved neurological and rare disease\ncommunities around the world. Our commercial portfolio includes the first and\nonly FDA-approved treatments for Parkinson’s disease psychosis and Rett\nsyndrome. We are developing the next wave of therapeutic advancements with a\nrobust and diverse pipeline that includes mid- to late-stage programs in\nAlzheimer’s disease psychosis and Lewy body dementia psychosis, along with\nearlier-stage programs that address other underserved patient needs. At\nAcadia, we’re here to be their difference. For more information, visit us at\nacadia.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Facadia.com%2Fen-us&esheet=54583306&newsitemid=20260804047448&lan=en-US&anchor=acadia.com&index=2&md5=4a4dbb4742aedbe7d7bad615239cfb11)\nand follow us on LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Facadia-pharmaceuticals%2F&esheet=54583306&newsitemid=20260804047448&lan=en-US&anchor=LinkedIn&index=3&md5=d76c8820ebbfd263779a4d92e6e39f04)\nand X\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fx.com%2Facadiapharma&esheet=54583306&newsitemid=20260804047448&lan=en-US&anchor=X&index=4&md5=29e4d1116ca0e6094c888510ca369e89)\n.\n\nNon-GAAP Financial Measures\n\nThis press release contains the following financial measures that do not\ncomply with U.S. generally accepted accounting principles (GAAP): non-GAAP\nadjusted net product sales for NUPLAZID for the second quarter of 2025 and\nnon-GAAP adjusted total revenues for the second quarter of 2025. In preparing\nthese non-GAAP financial results, the Company includes adjustments made to\nreflect the impact of a change in estimate related to NUPLAZID IRA rebate\naccruals. Please refer to our press release dated February 25, 2026, for\nadditional details. These non-GAAP financial measures complement GAAP results\nand are used by management to analyze financial performance and evaluate\nperiod-to-period changes. Management believes these non-GAAP financial\nmeasures are useful to investors and other users of the Company’s financial\nstatements to facilitate period-to-period comparability. These non-GAAP\nfinancial measures are not meant to be considered as a substitute for\ncomparable GAAP measures; should be read in conjunction with the Company’s\nconsolidated financial statements prepared in accordance with GAAP; have no\nstandardized meaning prescribed by GAAP; and are unlikely to be comparable\nwith non-GAAP disclosures released by other companies.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Forward-looking\nstatements include all statements other than statements of historical fact and\ncan be identified by terms such as “may,” “will,” “should,”\n“could,” “would,” “expects,” “plans,” “anticipates,”\n“believes,” “estimates,” “projects,” “predicts,”\n“potential,” “guidance,” “continue” and similar expressions\n(including the negative thereof) intended to identify forward-looking\nstatements. Forward-looking statements contained in this press release,\ninclude, but are not limited to, statements about: (i) our business strategy,\nobjectives and opportunities, including support for and innovations in our\npipeline assets and business development opportunities, sales growth for\nDAYBUE and uptake in DAYBUE STIX, and potential for enhanced shareholder\nvalue; (ii) the momentum and expectations for NUPLAZID with the expanded sales\nforce, (iii) the FDA’s potential review of a new drug application for\nremlifanserin as a treatment for Alzheimer’s disease psychosis, (iv) the\nreceipt and timing of the topline results of the RADIANT Phase 2 study, the\ntransformational opportunity of those results, and the enrollment of the Phase\n3 portion of the RADIANT development program, (v) potential approval of DAYBU\n(trofinetide) in the European Union, (vi) plans for, including timing,\ndevelopment and progress of commercialization or regulatory timelines for our\nproducts and our product candidates; (vii) benefits to be derived from and\nefficacy of our products, including the potential advantages of our products;\nand (viii) our estimates regarding our future financial performance,\nprofitability, capital requirements or expenses, including our full year 2026\nfinancial guidance and anticipated net product sales by the end of 2028.\nForward-looking statements are subject to known and unknown risks,\nuncertainties, assumptions and other factors that may cause our actual\nresults, performance or achievements to differ materially and adversely from\nthose anticipated or implied by our forward-looking statements. Such risks,\nuncertainties and other factors include, but are not limited to: our\ndependency on the continued successful commercialization of our products and\nour ability to maintain or increase sales of our products; the success of our\nplans to continue commercial growth; the costs of our commercialization plans\nand development programs, and the financial impact or revenues from any\ncommercialization we undertake; our ability to obtain necessary regulatory\napprovals for our product candidates and, if and when approved, market\nacceptance of our products; the risks associated with clinical trials and\ntheir outcomes, including risks of unsuccessful enrollment and negative or\ninconsistent results; our dependence on third-party collaborators, clinical\nresearch organizations, manufacturers, suppliers and distributors; the impact\nof competitive products and therapies; our ability to generate or obtain the\nnecessary capital to fund our operations; our ability to grow, equip and train\nour specialized sales forces; our ability to manage the growth and complexity\nof our organization; our ability to maintain, protect and enhance our\nintellectual property; and our ability to continue to stay in compliance with\napplicable laws and regulations. Given the risks and uncertainties, you should\nnot place undue reliance on these forward-looking statements. For a discussion\nof these and other risks, uncertainties and other factors that may cause our\nactual results, performance or achievements to differ, please refer to our\nannual report on Form 10-K for the year ended December 31, 2025 as well as our\nsubsequent filings with the Securities and Exchange Commission from time to\ntime. The forward-looking statements contained herein are made as of the date\nhereof, and we undertake no obligation to update them after this date, except\nas required by law.\n ACADIA PHARMACEUTICALS INC.                                                                                                              \n \n                                                                                                                                        \n \nCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS                                                                                         \n \n                                                                                                                                        \n \n(in thousands, except per share amounts)                                                                                                \n \n                                                                                                                                        \n \n(Unaudited)                                                                                                                             \n                                                                                                                                          \n                                                  Three Months Ended June 30,                   Six Months Ended June 30,                 \n                                                  2026                     2025                 2026                     2025             \n Revenues                                                                                                                                 \n Product sales, net                               $       307,959          $       264,566      $       576,021          $       508,882  \n Total revenues                                           307,959                  264,566              576,021                  508,882  \n Operating expenses                                                                                                                       \n Cost of product sales ((1)(2))                           28,316                   20,734               53,107                   41,126   \n Research and development ((2))                           81,555                   77,951               158,423                  156,216  \n Selling, general and administrative ((2))                160,252                  133,507              331,271                  259,877  \n Total operating expenses                                 270,123                  232,192              542,801                  457,219  \n (Loss) income from operations                            37,836                   32,374               33,220                   51,663   \n Interest income, net                                     7,990                    7,243                16,045                   15,144   \n Other income                                             647                      594                  1,189                    1,183    \n Income before income taxes                               46,473                   40,211               50,454                   67,990   \n Income tax expense                                       14,973                   13,545               15,317                   22,337   \n Net income                                       $       31,500           $       26,666       $       35,137           $       45,653   \n Earnings per share:                                                                                                                      \n Basic                                            $       0.18             $       0.16         $       0.21             $       0.27     \n Diluted                                          $       0.18             $       0.16         $       0.20             $       0.27     \n Weighted average common shares outstanding:                                                                                              \n Basic                                                    171,603                  167,827              171,063                  167,321  \n Diluted                                                  172,851                  168,681              172,890                  168,219  \n                                                                                                                                          \n ((1)) Includes license fees and royalties                                                                                                \n                                                                                                                                          \n ((2)) Includes the following stock-based compensation expense                                                                            \n                                                                                                                                          \n Cost of product sales                            $       510              $       18           $       838              $       352      \n Research and development                         $       4,746            $       4,477        $       8,888            $       7,910    \n Selling, general and administrative              $       11,684           $       9,845        $       21,912           $       17,458   \n\n ACADIA PHARMACEUTICALS INC.                                                                      \n \n                                                                                                \n \nCONDENSED CONSOLIDATED BALANCE SHEETS                                                           \n \n                                                                                                \n \n(in thousands)                                                                                  \n \n                                                                                                \n \n(Unaudited)                                                                                     \n                                                                                                  \n                                                       June 30,               December 31,        \n                                                       \n2026                  \n2025               \n                                                       (unaudited)                                \n Assets                                                                                           \n Cash, cash equivalents and investment securities      $       956,474        $        819,686    \n Accounts receivable, net                                      150,642                 121,457    \n Interest and other receivables                                15,688                  26,774     \n Inventory                                                     32,372                  34,670     \n Prepaid expenses and other current assets                     69,369                  59,526     \n Total current assets                                          1,224,545               1,062,113  \n Property and equipment, net                                   17,107                  7,511      \n Operating lease right-of-use assets                           69,424                  47,354     \n Intangible assets, net                                        103,448                 108,893    \n Restricted cash                                               7,846                   7,845      \n Long-term inventory                                           76,301                  76,704     \n Deferred tax assets                                           240,679                 249,879    \n Other assets                                                  3,550                   3,896      \n Total assets                                          $       1,742,900      $        1,564,195  \n Liabilities and stockholders’ equity                                                             \n Accounts payable                                      $       44,566         $        10,903     \n Accrued liabilities                                           316,870                 266,211    \n Total current liabilities                                     361,436                 277,114    \n Operating lease liabilities                                   59,547                  40,554     \n Other long-term liabilities                                   15,308                  19,137     \n Total liabilities                                             436,291                 336,805    \n Total stockholders’ equity                                    1,306,609               1,227,390  \n Total liabilities and stockholders’ equity            $       1,742,900      $        1,564,195  \n\n Table 1. ACADIA PHARMACEUTICALS INC.                                     \n \n                                                                        \n \nNON-GAAP RECONCILIATION                                                 \n \n                                                                        \n \n(in millions)                                                           \n \n                                                                        \n \n(Unaudited)                                                             \n                                                                          \n                                           2Q25               2Q26        \n GAAP NUPLAZID Net Sales                   $   168.5          $    183.2  \n Allocation of 2025 Amount                 $   (2.4   )       $    —      \n Non-GAAP Adjusted NUPLAZID Net Sales      $   166.1          $    183.2  \n DAYBUE products Net Sales                 $   96.1           $    124.8  \n Non-GAAP Adjusted Total Revenues          $   262.2          $    308.0  \n\n\n \n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260804047448/en/\n(https://www.businesswire.com/news/home/20260804047448/en/)\n\nInvestor Contact: \n\nAcadia Pharmaceuticals Inc.\n\nAl Kildani\n\n(858) 261-2872\n\nir@acadia-pharm.com (mailto:ir@acadia-pharm.com)\n\nAcadia Pharmaceuticals Inc.\n\nJessica Tieszen\n\n(858) 261-2950\n\nir@acadia-pharm.com (mailto:ir@acadia-pharm.com)\n\nMedia Contact: \n\nAcadia Pharmaceuticals Inc.\n\nDeb Kazenelson\n\n(818) 395-3043\n\nmedia@acadia-pharm.com (mailto:media@acadia-pharm.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-08-04T20:05:01.1135977Z","server_sent_at_ms":1785873901113},"received_at":"2026-08-04T20:05:01.180Z","source_url":"https://www.businesswire.com/news/home/20260804047448/en/"},"analysis":{"id":"97539","press_release_id":"108527","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"earnings","narrative":"Acadia reported Q2 revenue of $308 million, up 17% year-over-year on an adjusted basis, with diluted EPS rising to $0.18 from $0.16 a year ago.\n\nDAYBUE sales surged 30% to $125 million, while NUPLAZID sales increased 10% to $183 million, prompting the company to raise its full-year 2026 revenue guidance to a range of $1.24 billion to $1.30 billion.\n\nManagement also highlighted that Phase 2 topline results for remlifanserin in Alzheimer’s disease psychosis are expected between September and October 2026.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Beat-and-raise driven by 30% Daybue growth; key Phase 2 data readout for remlifanserin expected this fall."},"keyFigures":{"eps":0.18,"revenue":308000000,"guidance":"FY26 total revenue $1.24B-$1.30B, raised from $1.22B-$1.28B; DAYBUE sales guidance raised to $480M-$510M","revenueYoy":"17%","customDimensions":{"cash":956000000,"r_and_d":82000000,"sg_and_a":160000000,"daybue_sales":125000000,"nuplazid_sales":183000000,"daybue_sales_yoy":"30%","nuplazid_sales_adj_yoy":"10%"}},"quotedText":"Acadia delivered an outstanding second quarter, highlighted by strong commercial execution across both DAYBUE and NUPLAZID, resulting in total revenue growth of 17% year-over-year on an adjusted basis","namedEntities":{"people":[{"name":"Catherine Owen Adams","role":"Chief Executive Officer"}],"products":["DAYBUE","DAYBUE STIX","NUPLAZID","remlifanserin","DAYBU"],"companies":[{"name":"Acadia Pharmaceuticals Inc.","ticker":"ACAD"}],"dollarAmounts":[{"amount":"$125 million","context":"Second quarter DAYBUE GAAP net sales"},{"amount":"$183 million","context":"Second quarter NUPLAZID GAAP net sales"},{"amount":"$308 million","context":"Second quarter GAAP total revenues"},{"amount":"$1.24 to $1.30 billion","context":"Increased full year 2026 total revenue guidance"},{"amount":"$956 million","context":"Cash, cash equivalents, and investment securities"}]},"materialImpact":{"score":4,"reasoning":"Strong Q2 results with 17% adjusted revenue growth driven by 30% uptake in DAYBUE, accompanied by a raise in full-year 2026 revenue guidance."},"tickerRelevance":{"others":[],"primary":"ACAD"},"globalImportance":25,"audienceRelevance":40,"eventTypeSecondary":["guidance_update","clinical_trial"],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"earnings_beat_and_raise","sectorWeight":"health_care","catalystNearTerm":true}},"event_type":"earnings","event_type_secondary":["guidance_update","clinical_trial"],"sentiment":"bullish","material_impact_score":4,"narrative":"Acadia reported Q2 revenue of $308 million, up 17% year-over-year on an adjusted basis, with diluted EPS rising to $0.18 from $0.16 a year ago.\n\nDAYBUE sales surged 30% to $125 million, while NUPLAZID sales increased 10% to $183 million, prompting the company to raise its full-year 2026 revenue guidance to a range of $1.24 billion to $1.30 billion.\n\nManagement also highlighted that Phase 2 topline results for remlifanserin in Alzheimer’s disease psychosis are expected between September and October 2026.","key_figures":{"eps":0.18,"revenue":308000000,"guidance":"FY26 total revenue $1.24B-$1.30B, raised from $1.22B-$1.28B; DAYBUE sales guidance raised to $480M-$510M","revenueYoy":"17%","customDimensions":{"cash":956000000,"r_and_d":82000000,"sg_and_a":160000000,"daybue_sales":125000000,"nuplazid_sales":183000000,"daybue_sales_yoy":"30%","nuplazid_sales_adj_yoy":"10%"}},"named_entities":{"people":[{"name":"Catherine Owen Adams","role":"Chief Executive Officer"}],"products":["DAYBUE","DAYBUE STIX","NUPLAZID","remlifanserin","DAYBU"],"companies":[{"name":"Acadia Pharmaceuticals Inc.","ticker":"ACAD"}],"dollarAmounts":[{"amount":"$125 million","context":"Second quarter DAYBUE GAAP net sales"},{"amount":"$183 million","context":"Second quarter NUPLAZID GAAP net sales"},{"amount":"$308 million","context":"Second quarter GAAP total revenues"},{"amount":"$1.24 to $1.30 billion","context":"Increased full year 2026 total revenue guidance"},{"amount":"$956 million","context":"Cash, cash equivalents, and investment securities"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-05T01:39:42.411Z","global_importance":25,"audience_relevance":40,"importance_components":{"tickerTier":"mid-cap","eventGravity":"earnings_beat_and_raise","sectorWeight":"health_care","catalystNearTerm":true}},"durationMs":226236,"modelName":"glm-4.7"}}